|
T3536 |
AZD1283
|
|
P2Y Receptor
|
|
AZD1283 is an effective P2Y12 receptor antagonist (EC50: 3.0 ug/kg/min, binding IC50: 11 nM). AZD1283 dose-dependently induced increases in blood flow and inhibition of ADP-induced platelet aggregation with antithromboti... |
|
T2368 |
Edoxaban Tosylate Monohydrate
|
DU-176b,DU-176b tosylate Monohydrate,Lixiana,Edoxaban |
Factor Xa
,
Thrombin
|
|
Edoxaban(DU-176) is an oral factor Xa (FXa) inhibitor in clinical development for stroke prevention. |
|
T27257 |
EMD-503982
|
EMD503982,EMD 503982 |
Factor Xa
|
|
EMD-503982 is a potential Factor Xa and Factor VIIa inhibitor with potential anticancer and antitumor activity for the study of thromboembolic and neurological disorders. |
|
T77124 |
Osocimab
|
BAY 1213790 |
FXR
|
|
Osocimab (BAY 1213790) is a potent anti-FXIa antibody with a Ki value of 2.4 nM and an EC50 value of 0.2 nM.Osocimab may reduce thrombosis through FXI inhibition.Osocimab is often used as an XI factor inhibitor, has an i... |
|
T2368L |
Edoxaban
|
Lixiana |
Factor Xa
,
Thrombin
|
|
Edoxaban (Lixiana) (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor with K i s of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban is an anticoagulant agent and is a... |
|
T70184 |
YM-60828 dihydrochloride
|
|
|
|
YM-60828 dihydrochloride is a Factor Xa (FXa) inhibitor and anticoagulant used in the treatment of venous thromboembolic disease. |
|
T71362 |
GCC-4401C free base
|
|
|
|
GCC-4401C free base is a factor Xa inhibitor similar to rivaroxaban that is currently under development for venous thromboembolic disease (VTE). |
|
T71096 |
GCC-4401C methanesulfonate
|
|
|
|
GCC-4401C methanesulfonate is a factor Xa inhibitor similar to rivaroxaban that is currently under development for venous thromboembolic disease (VTE). |
|
T70233 |
Efegatran HCl
|
|
|
|
Efegatran, also known as GYKI-14166, RGH-2958 and LY294468, a thrombin inhibitor which is being developed by IVAX for the potential treatment of thromboembolic disorders. |
|
T63239 |
FXa-IN-1
|
|
|
|
FXa-IN-1 is an FXa inhibitor with an IC50 value of 3 nM and a Ki value of 0.7 nM that exhibits good oral bioavailability and half-life (in vivo) and can be used to study thromboembolic diseases. |
|
T11100 |
DS-1040 Tosylate
|
|
Others
|
|
DS-1040 Tosylate is an oral active, selective thrombolytic inhibitor with IC50s of 5.92 nM and 8.01 nM for human and rat TAFIa, is an orally active, selective inhibitor of activated thrombin-activatable fibrinolysis inhi... |
|
T60576 |
Cyproheptadine
|
|
|
|
Cyproheptadine is a potent and orally active antagonist of the 5-HT 2A receptor. Cyproheptadine has antidepressant and antiserotonergic effects. Cyproheptadine also has antiplatelet and thromboprotective activities that ... |
|
T64126 |
Edoxaban hydrochloride
|
|
|
|
Edoxaban (DU-176b) hydrochloride is a potent, selective, orally active, direct inhibitor of Factor Xa (FXa), acting on human free FXa (Ki: 0.561 nM) and thrombinogenase (Ki: 2.98 nM). Edoxaban hydrochloride is more than ... |
|
T76894 |
Abelacimab
|
|
|
|
Abelacimab (MAA868), a fully human IgG1 monoclonal antibody, targets and binds with high affinity to FXI's catalytic structural domain. This interaction ensures FXI remains in its zymogen form, effectively inhibiting act... |
|
T64099 |
FXIa-IN-9
|
|
|
|
FXIa-IN-9 (compound 3f) is a potent, selective inhibitor of FXIa, demonstrating strong binding affinity through hydrogen bond formation (human FXIa K i : 0.17 nM, rabbit FXIa K i : 0.5 nM). It exhibits anticoagulant prop... |
